SCHEMBL2818670

SCHEMBL2818670

COC(=O)c1cncn1C1c2ccc(Cl)cc2C(=O)C1(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 3/20 0.45
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
GAA P10253 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
F2 P00734 1/20 0.36
PLAU P00749 1/20 0.36
KLKB1 P03952 1/20 0.36
ELANE P08246 1/20 0.36
CYP11B1 P15538 1/20 0.35
MAPK1 P28482 1/20 0.34
TSHR P16473 1/20 0.34
IDO1 P14902 5/20 0.34
ADAMTS5 Q9UNA0 1/20 0.33
CCNC P24863 1/20 0.33
CDK8 P49336 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2818227 0.84 CYP11B2 (0.58) CYP11B2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2817705 0.80 CYP11B2 (0.45) CYP11B2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2819526 0.79 CYP11B2 (0.53) CYP11B2ALDH1A1CYP11B1IDO1CYP1A2
SCHEMBL2820667 0.79 CYP11B2 (0.53) CYP11B2ALDH1A1CYP11B1IDO1CYP1A2
SCHEMBL9777264 0.76 CYP11B2 (0.56) CYP11B2ALDH1A1KDM4EHSD17B10CYP11B1
SCHEMBL843144 0.74 CYP11B2 (0.40) CYP11B2ALDH1A1KDM4EHSD17B10GAA
SCHEMBL1098831 0.72 CYP11B2 (0.79) CYP11B2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1098830 0.72 CYP11B2 (0.79) CYP11B2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2816749 0.72 GHSR (0.40) CYP11B2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL842386 0.72 CYP11B2 (0.48) CYP11B2ALDH1A1KDM4ECYP11B1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436035-B2 Organic compounds NOVARTIS AG (CH) 2013-05-07 US disclosed
EP-2213668-A2 Imidazoles as aldosterone synthase inhibitors Novartis AG (CH) 2010-08-04 EP disclosed
US-20100048562-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-02-25 US disclosed
EP-2094680-A2 IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS Novartis AG (CH) 2009-09-02 EP disclosed
WO-2008076336-A2 IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048562-A1 ORGANIC COMPOUNDS CYP11B1, HSD11B1, CYP17A1 CYP11B2 6/4885ALDH1A1 289/4885SMN1; SMN2 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.